Erratum to “C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV” [American Journal of Preventive Cardiology 3C (2020) 100091] (American Journal of Preventive Cardiology (2020) 3, (S266666772030091X), (10.1016/j.ajpc.2020.100091))

Adam J. Nelson, Rishi Puri, Danielle M. Brennan, Todd J. Anderson, Leslie Cho, Christie M. Ballantyne, John J. P. Kastelein, Wolfgang Koenig, Helina Kassahun, Ransi M. Somaratne, Scott M. Wasserman, Steven E. Nissen, Stephen J. Nicholls

Research output: Contribution to journalErratum/CorrigendumAcademic


The publisher regrets to inform the readers that the Declaration of Competing Interest statement was not included in the published version of this article. The appropriate Declaration/Competing Interest statements provided by the Authors is as below. Dr Puri has received consulting fees from Cerenis, Sanofi, and Amgen. Dr Anderson was the local principal investigator on clinical research studies for Amgen Inc and Dalcor. Dr.Ballantyne has received grant/research support (paid to institution, not individual) from Abbott Diagnostic, Amarin, Amgen,Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostics, Sanofi-Synthelabo, National Institutes of Health, AmericanHeart Association, and American Diabetes Association; and has served as a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer, Regeneron, Roche Diagnostics, and Sanofi-Synthelabo. Dr. Kastelein has received personal consulting fees from Amgen, CiVi Biopharma, Sanofi,Affiris, Akarna Therapeutics, Amgen, CSL Behring, Regeneron,Staten Biotech, Madrigal, The Medicines Company, Kowa, Lilly, Esperion, Gemphire, Ionis Pharmaceuticals, and Akcea Phar-maceuticals. Dr. Koenig has received personal fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, GlaxoSmithKline, DalCor, Sanofi, Berlin-Chemie, Kowa, Corvidia, Bristol-Myers Squibb, Daiichi-Sankyo, and Amgen; and has received grants and nonfinancial support from Roche Diagnostics, Beckmann, Singulex, and Abbott. Dr. Kassahun is an employee of and stockholder in Amgen. Dr. Somaratne is a current employee of Epirium Bio, Inc. San Diego CA; is a former employee of Amgen; is identified as an inventor on at least one pending patent application related to evolocumab Dr. Wasserman is a former employee of Amgen. Dr. Nissen's institution (ClevelandClinic Center for Clinical Research) has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen, Cerenis, Eli Lilly, Esperion, Novartis, Pfizer, The Medicines Company, MyoKardia, Takeda, and Orexigen; he is involved in these clinical trials, but receives no personal remuneration for his participation; and consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received research support from AstraZeneca, Amgen Inc., Anthera, Eli Lilly, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche,Sanofi-Regeneron, and LipoScience; and has received consultingfees and honoraria from AstraZeneca, Eli Lilly, Anthera,Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, and Boehringer Ingelheim. The publisher would like to apologise for any inconvenience caused.
Original languageEnglish
Article number100153
JournalAmerican Journal of Preventive Cardiology
Publication statusPublished - 1 Jun 2021

Cite this